Biorphen is a medication generally used in clinical settings for the symptomatic management of symptoms related to clinically important hypotension. The therapeutic benefit involves supporting the stabilization of systemic pressure, which supports symptoms related to systemic imbalance.

---

Key Therapeutic Applications

This medication is relevant for use in conditions where clinically important hypotension occurs, particularly when conditions produce significant symptomatic burden and during periods of increased physiological stress, such as surgical procedures requiring anesthesia (general, spinal, or neuraxial). Biorphen is applied across domains where additional symptomatic support is needed to address symptom clusters that may become intense or disruptive. The medication is relevant for easing symptoms that interfere with daily comfort by helping manage blood pressure fluctuations.

“This supportive relief generally helps ease the overall symptom load associated with acute circulatory instability.”

In this context, Biorphen provides supportive relief when symptoms interfere with routine activities, contributing to blood pressure stabilization and supporting patients during episodes of heightened discomfort.

---

Quick Fact: Supportive Management for Clinically Important Low Blood Pressure The medication is commonly used to help manage symptoms related to heightened physiological activity that occur during challenging symptomatic phases.

Who Can and Cannot Use Biorphen?

The official regulatory eligibility profile for Biorphen (Phenylephrine IV) strictly classifies populations into allowed, prohibited, and conditional use groups based on specific patient conditions and age.

The medicine is contraindicated and must not be used by patients with a known hypersensitivity to the formulation or by those currently taking, or who have taken within the last 14 days, non-selective Monoamine Oxidase Inhibitors (MAOIs).

Biorphen is indicated for use in adults. Its safety and effectiveness have not been established in the pediatric population. For older adults, caution is advised, and dose selection must be cautious.

Use is conditional and requires close monitoring in several groups, including individuals with pre-existing cardiovascular conditions such as severe arteriosclerosis, partial heart block, or underlying heart failure. Patients with End-Stage Renal Disease show increased drug responsiveness, while those with liver cirrhosis show decreased responsiveness. During pregnancy and lactation, use is restricted and should occur only if clearly needed.

Biorphen Interactions with other medicines and products

Biorphen (Phenylephrine hydrochloride) interacts with several classes of medicinal products, primarily by either augmenting or opposing its alpha-adrenergic pressor effect, as documented in regulatory information.

Contraindicated and High-Risk Combinations

Certain combinations are strictly contraindicated due to the high risk of severe adverse outcomes. The use of Biorphen is prohibited with Non-selective Monoamine Oxidase Inhibitors (MAOIs), including products like Isocarboxazid or Phenelzine, as this pharmacokinetic interaction (reduced clearance) can lead to severe paroxysmal hypertension and hyperthermia. Furthermore, the imaging agent Iobenguane I 123 is contraindicated due to documented receptor competition that may reduce the diagnostic agent’s effect.

Pharmacodynamic Interactions

Officially documented interactions that potentiate Biorphen's blood pressure effect include: Oxytocic Drugs (e.g., Methylergonovine), which augment the pressor response with a potential risk of hemorrhagic stroke; Halogenated Volatile Anesthetics (e.g., Isoflurane), which increase the risk of perioperative hypertensive crisis and arrhythmias; and medicines like Tricyclic Antidepressants, Steroids, and Norepinephrine Transport Inhibitors.

Conversely, Alpha-adrenergic Antagonists and Centrally-acting Sympatholytic Agents are documented to reduce or antagonize Biorphen’s pressor effect.

Timing and Population Constraints

Due to the persistent risk of MAOI interaction, a mandatory separation period of 14 to 15 days must be observed after the MAOI is discontinued. The regulatory label also notes that the pressor response to Biorphen is increased in patients with autonomic dysfunction (such as spinal cord injuries), making pressor-potentiating interactions potentially more significant in this population.

How Biorphen Works

---

Selective Activation of Vascular Alpha-1 Receptors

The primary mechanism of Biorphen is its function as a direct agonist at the Alpha-1 Adrenergic Receptor (alpha1-AR), which are selectively concentrated on the smooth muscle of peripheral blood vessels. This interaction initiates the fundamental signal for muscle contraction and defines the drug's selectivity, as it exhibits minimal to no agonism at beta-adrenergic receptors (beta-AR).

---

Intracellular Calcium Cascades and Vascular Contraction

Upon alpha1-AR binding, a swift Gq-protein coupled intracellular cascade is initiated, culminating in the release of calcium ions ( Ca^2+) from the smooth muscle cells' internal stores. This surge in Ca^2+ is the essential molecular event that causes the sustained shortening of the muscle fibers, leading to widespread vasoconstriction of both arteries and veins.

---

Modulation of Systemic Resistance and Reflex Feedback

The resulting generalized vasoconstriction significantly increases Systemic Vascular Resistance (SVR) and enhances Venous Return to the heart. These combined hemodynamic changes rapidly produce an elevation in arterial pressure. The body detects this pressor effect via the baroreflex, which triggers a predictable, compensatory reflex slowing of the heart rate (bradycardia), acting as a homeostatic constraint on the pressor effect.

How Biorphen is Used: Administration Guidelines

Biorphen (phenylephrine hydrochloride injection) is used exclusively under the supervision of a healthcare professional in acute clinical settings, with administration patterns following established clinical standards. The medicine is administered via the Intravenous (IV) route, specifically as an IV bolus injection for rapid effects or a continuous IV infusion for sustained support.

---

Dosing and Frequency Patterns

The dosage of Biorphen is not fixed but is carefully adjusted, or titrated to effect, based on the patient's pressor response. For acute hypotension during anesthesia, the usual starting IV bolus dose is between 40 mcg and 100 mcg. Additional doses, which may be up to 200 mcg, can be administered every one to two minutes as needed. When administered as a continuous infusion, the typical starting rate is 10 mcg/minute to 35 mcg/minute, with a maximum recommended rate not to exceed 200 mcg/minute. The overall course of treatment is typically short-term, intended for acute hemodynamic stabilization.

---

Preparation and Special Conditions

Specific preparation rules govern the use of Biorphen based on its concentration. The 10 mg/mL concentrate MUST BE DILUTED with approved solutions, such as 0.9% Sodium Chloride, prior to administration. Conversely, the 0.1 mg/mL solution is ready-to-use and MUST NOT be diluted. It is recognized that volume depletion or acidosis should be corrected before or during the use of Biorphen to optimize its effect. For specific populations, clinical data indicates that lower doses may be needed for patients with renal impairment, while those with hepatic impairment may require higher doses.

Research Evidence Overview

This section summarizes the published clinical research and study patterns that form the official evidence base for Biorphen (phenylephrine injection). The information below details what studies have explored, the types of patient groups monitored, and where the scientific evidence remains limited or uncertain.

---

Evidence for Use in Clinically Important Hypotension During Anesthesia

The core research exploring acute, low blood pressure (hypotension) observed during surgery, particularly in the context of anesthesia, consists primarily of Randomized Controlled Trials (RCTs). Research examined changes in physiological parameters and acute hemodynamic metrics, such as Mean Arterial Pressure (MAP) and Systolic Blood Pressure (SBP). Findings from these studies describe patterns related to blood pressure maintenance during the surgical window. However, the outcomes reported were mainly based on surrogate physiological endpoints rather than long-term clinical results. Observations related to maternal cardiac output have been mixed in comparison studies, and an association with bradycardia (a slowed heart rate) and observations of high blood pressure has been described in some populations.

---

Evidence for Use in Acute Vasodilatory Shock

Research for the use of Biorphen in acute vasodilatory states, such as septic shock, involves a limited number of comparative RCTs and observational studies. These studies explored managing severe low blood pressure in adult patients within the intensive care setting, examining outcomes monitoring physiological strain. Certainty remains low for this use, as comparative evidence for the initial management phase is lacking. Some research suggests that Biorphen in this context may be associated with uncertain effects on blood flow to internal organs.

---

Research on Specific Populations and Uncertainty

Research has evaluated several defined patient groups, including adult surgical populations and adult parturients (pregnant women) undergoing Cesarean delivery under spinal anesthesia. Fetal and neonatal outcomes were examined in these studies. The majority of the research was evaluated in scenarios examining temporary physiological imbalance; consequently, follow-up durations were limited. Long-term effects are not fully established, and evidence quality varies across studies. Subgroup findings for many complex patient groups are uncertain, and research is ongoing to address these gaps regarding the cardiovascular parameters.

Key Studies & References

1. Impact of Phenylephrine on Cardiac Output and Uteroplacental Circulation in Obstetric Anesthesia: A Randomized Controlled Trial

Common questions about Biorphen (FAQ)

Q: What is Biorphen used for?

A: Biorphen is a prescription medication approved for the temporary control of ventricular rate and rhythm in certain supraventricular tachycardias (SVT) and for noncompensatory sinus tachycardia when, in the physician’s judgment, specific intervention is required. It may also be used in the perioperative setting for temporary control of high heart rate or blood pressure.

Q: How does Biorphen work?

A: Biorphen belongs to a class of drugs known as beta-blockers. Its action involves slowing the rate of heart contractions.

Q: What are the most common side effects of Biorphen?

A: The most frequently reported adverse effects associated with Biorphen are low blood pressure (hypotension) and a slow heart rate (bradycardia). Other common effects may include injection site reactions and dizziness. Not everyone experiences side effects.

Official Storage and Disposal Requirements

Biorphen (phenylephrine HCl) injection must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from light and inspected for discoloration or particulate matter before use.

Stability and Handling:

• Undiluted: Store in the original container at room temperature.
• Diluted: Use the prepared solution within 4 hours at room temperature, or store refrigerated and use within 24 hours.
• Discard: Any unused portion of the solution must be immediately discarded.

Disposal Requirements:

Biorphen's active ingredient is classified as a hazardous pharmaceutical waste (P-listed waste) under federal regulations. Disposal must be performed in accordance with all local, state, and national environmental control regulations. The product must not be disposed of down the drain, in household trash, or released into the environment, and typically requires professional incineration.